VERAXA Biotech AG (NASDAQ: VRXA) has announced the appointment of Carl von Halem as interim chief financial officer, effective immediately. He succeeds Torsten Bürgermeister, whose departure was not detailed. The company stated that it is in the final stages of discussions with a permanent CFO candidate expected to support its next phase of expansion and operational growth, with an update to be provided in due course.
Von Halem currently serves as chief financial officer of Xlife Sciences and played a key role in VERAXA’s public listing. The company cited his experience in corporate finance, life sciences and technology-driven businesses, as well as his familiarity with VERAXA’s operations and strategic development, as key qualifications for leading the finance function during the transition. His appointment comes at a critical time as VERAXA advances its pipeline of antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
For more details, the full press release is available at https://nnw.fm/BjjY6.
About VERAXA Biotech AG (NASDAQ: VRXA): At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
This leadership change underscores VERAXA's commitment to strengthening its financial leadership as it prepares for the next stage of growth, including potential clinical milestones and partnerships. The appointment of von Halem, who already has deep knowledge of the company, is expected to provide stability while the board evaluates a permanent CFO.
